Lung Cancer

Cell Genesys Reports Antitumor Activity In Phase I/II GVAX Vaccine Trial

Published in Cancer Weekly, May 29th, 2001

Cell Genesys, Inc. (CEGE) reported interim clinical data from its multicenter Phase I/II GVAX^R lung cancer vaccine trial that demonstrate objective evidence of antitumor activity including a major response rate of 18% in patients with advanced non small-cell lung cancer who have failed chemotherapy and/or radiation therapy.

These data were presented on behalf of the GVAX Lung Cancer Clinical investigators by John Nemunaitis, MD, of U.S. Oncology on May 13, 2001, at the American Society of Clinical Oncology (ASCO) Meeting in San Francisco, California.

The interim clinical trial data include results on 30 currently evaluable patients with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-05-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry